FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063481154> ?p ?o ?g. }

• W2063481154 endingPage "166" @default.
• W2063481154 startingPage "159" @default.
• W2063481154 abstract "To determine if stratification of limited stage small cell lung cancer (LSCLC) patients by pre-treatment pulmonary function test (PFT) prognostic indicators predicts for treatment-related toxicity risks and survival following concurrent chemoradiation.From 1989 to 1999, 215 LSCLC patients received six cycles of alternating cyclophosphamide/doxorubicin/vincristine and etoposide/cisplatin (EP). Thoracic radiation (RT) was initiated only with EP and at cycle 2 or 3. RT dose was: 40 Gy/15 fractions/3 weeks or 50 Gy/25 fractions/5 weeks. RT fields encompassed gross and suspected microscopic disease with a 2 cm margin. Pre-treatment PFT values analyzed included forced expiratory volume in 1s (FEV1) (in liter and as % predicted) and diffusion capacity for carbon monoxide (DLCO) (as % predicted). The marker for toxicity during concurrent chemoradiation was the duration of any RT breaks initiated for severe hematologic or locoregional symptomatology. Patient outcomes were analyzed for associations between recognized PFT cut-offs (FEV1 <2l, > or =2l; FEV1 <60%, > or =60% predicted; DLCO <60%, > or =60% predicted), toxicity rates, and survival.For the whole study cohort, median, 2- and 5-year overall survivals were: 14.7 months, 22.7 and 7.2%, respectively. Fifty-six patients (26%) required treatment breaks due to toxicity. FEV1 and DLCO results were available for 96 (45%) and 86 (40%) patients, respectively. Two thirds of FEV1s measured were <2l. On statistical analysis, the incidence of toxicity-related interruptions was significant for DLCO<60% (P=0.043), suggestive for FEV1<2l (P=0.1) and non-significant for FEV1<60%. Patients with simultaneous DLCO<60% and FEV1<2l showed a trend toward increase toxicity risk (P=0.1). For selected PFT measures, median overall survivals were: 12.7 months versus 14.8 months for DLCO<60% versus > or =60%; 13.4 months versus 17.7 months for FEV1<2l versus > or =2l; 15.4 months versus 19.9 months for DLCO<60% + FEV1<2l versus DLCO> or =60% + FEV1> or =2l. Although absolute differences favored all patients with PFT values above the prognostic cut-offs, differences were not statistically significant on this analysis. Patients with both a treatment break and a DLCO<60% had the poorest median survival of all patient subsets, at 11.4 months (P=0.09).Impaired DLCO (i.e. <60%) is a novel predictor of increased treatment-related toxicity leading to interruptions. The present study suggests a probable role for DLCO and FEV1 (in l) as prognostic factors for predicting survival but larger patient samples are required for confirmation. Patients with impaired DLCOs experiencing treatment interruptions have the poorest survival. Assessment of pre-treatment PFTs contributes to determining optimal management strategies for LSCLC patients receiving definitive chemoradiation." @default.
• W2063481154 created "2016-06-24" @default.
• W2063481154 creator A5007577884 @default.
• W2063481154 creator A5014161715 @default.
• W2063481154 creator A5054903358 @default.
• W2063481154 creator A5063411006 @default.
• W2063481154 creator A5065708016 @default.
• W2063481154 creator A5066559117 @default.
• W2063481154 creator A5091101559 @default.
• W2063481154 date "2004-02-01" @default.
• W2063481154 modified "2023-09-26" @default.
• W2063481154 title "Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer patients treated with concurrent chemoradiation" @default.
• W2063481154 cites W1885320430 @default.
• W2063481154 cites W1986783484 @default.
• W2063481154 cites W1988158857 @default.
• W2063481154 cites W2045410673 @default.
• W2063481154 cites W2058732484 @default.
• W2063481154 cites W2062505977 @default.
• W2063481154 cites W2076880391 @default.
• W2063481154 cites W2124353451 @default.
• W2063481154 cites W2170640134 @default.
• W2063481154 cites W2323020638 @default.
• W2063481154 cites W2410543196 @default.
• W2063481154 doi "https://doi.org/10.1016/j.lungcan.2003.08.026" @default.
• W2063481154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14739036" @default.
• W2063481154 hasPublicationYear "2004" @default.
• W2063481154 type Work @default.
• W2063481154 sameAs 2063481154 @default.
• W2063481154 citedByCount "19" @default.
• W2063481154 countsByYear W20634811542012 @default.
• W2063481154 countsByYear W20634811542015 @default.
• W2063481154 countsByYear W20634811542018 @default.
• W2063481154 countsByYear W20634811542019 @default.
• W2063481154 countsByYear W20634811542021 @default.
• W2063481154 countsByYear W20634811542022 @default.
• W2063481154 countsByYear W20634811542023 @default.
• W2063481154 crossrefType "journal-article" @default.
• W2063481154 hasAuthorship W2063481154A5007577884 @default.
• W2063481154 hasAuthorship W2063481154A5014161715 @default.
• W2063481154 hasAuthorship W2063481154A5054903358 @default.
• W2063481154 hasAuthorship W2063481154A5063411006 @default.
• W2063481154 hasAuthorship W2063481154A5065708016 @default.
• W2063481154 hasAuthorship W2063481154A5066559117 @default.
• W2063481154 hasAuthorship W2063481154A5091101559 @default.
• W2063481154 hasConcept C126322002 @default.
• W2063481154 hasConcept C126894567 @default.
• W2063481154 hasConcept C141071460 @default.
• W2063481154 hasConcept C16020263 @default.
• W2063481154 hasConcept C165637977 @default.
• W2063481154 hasConcept C2776694085 @default.
• W2063481154 hasConcept C2776755627 @default.
• W2063481154 hasConcept C2777714996 @default.
• W2063481154 hasConcept C2778119113 @default.
• W2063481154 hasConcept C2779429289 @default.
• W2063481154 hasConcept C2781047374 @default.
• W2063481154 hasConcept C29730261 @default.
• W2063481154 hasConcept C3018587741 @default.
• W2063481154 hasConcept C509974204 @default.
• W2063481154 hasConcept C71924100 @default.
• W2063481154 hasConcept C72563966 @default.
• W2063481154 hasConcept C75603125 @default.
• W2063481154 hasConcept C88879693 @default.
• W2063481154 hasConcept C90924648 @default.
• W2063481154 hasConceptScore W2063481154C126322002 @default.
• W2063481154 hasConceptScore W2063481154C126894567 @default.
• W2063481154 hasConceptScore W2063481154C141071460 @default.
• W2063481154 hasConceptScore W2063481154C16020263 @default.
• W2063481154 hasConceptScore W2063481154C165637977 @default.
• W2063481154 hasConceptScore W2063481154C2776694085 @default.
• W2063481154 hasConceptScore W2063481154C2776755627 @default.
• W2063481154 hasConceptScore W2063481154C2777714996 @default.
• W2063481154 hasConceptScore W2063481154C2778119113 @default.
• W2063481154 hasConceptScore W2063481154C2779429289 @default.
• W2063481154 hasConceptScore W2063481154C2781047374 @default.
• W2063481154 hasConceptScore W2063481154C29730261 @default.
• W2063481154 hasConceptScore W2063481154C3018587741 @default.
• W2063481154 hasConceptScore W2063481154C509974204 @default.
• W2063481154 hasConceptScore W2063481154C71924100 @default.
• W2063481154 hasConceptScore W2063481154C72563966 @default.
• W2063481154 hasConceptScore W2063481154C75603125 @default.
• W2063481154 hasConceptScore W2063481154C88879693 @default.
• W2063481154 hasConceptScore W2063481154C90924648 @default.
• W2063481154 hasIssue "2" @default.
• W2063481154 hasLocation W20634811541 @default.
• W2063481154 hasLocation W20634811542 @default.
• W2063481154 hasOpenAccess W2063481154 @default.
• W2063481154 hasPrimaryLocation W20634811541 @default.
• W2063481154 hasRelatedWork W144799118 @default.
• W2063481154 hasRelatedWork W1979411093 @default.
• W2063481154 hasRelatedWork W2066165267 @default.
• W2063481154 hasRelatedWork W2083778963 @default.
• W2063481154 hasRelatedWork W2133674561 @default.
• W2063481154 hasRelatedWork W2151686129 @default.
• W2063481154 hasRelatedWork W4220786974 @default.
• W2063481154 hasRelatedWork W4299369722 @default.
• W2063481154 hasRelatedWork W138201130 @default.
• W2063481154 hasRelatedWork W2404134048 @default.
• W2063481154 hasVolume "43" @default.

• next